Vertex will utilise the Diamond Synchrotron, the largest scientific facility to be built in the UK for 40 years, to advance its research programmes for the treatment of serious diseases. With a UK office in Milton Park in South Oxfordshire, Vertex is well-positioned to use the Chilton-based synchrotron, which was officially opened by Her Majesty the Queen in October 2007.
Diamond is able to produce intensely focused synchrotron light in the form of X-rays, infrared and ultraviolet, which will be used by Vertex and other companies to investigate the atomic details of how novel drugs bind to proteins involved in human diseases.
These types of structural studies have become a cornerstone for the understanding of biological processes and an invaluable element of modern medical research, leading to more rational design of therapeutic agents. Diamond will enable Vertex to generate this information at a significantly higher rate than currently possible.
Founded in the USA in 1989, Vertex has been involved in rational drug design from its outset; using synchrotron techniques to determine the structures of biological proteins that play a role in serious diseases in order to inform more intelligent creation of therapeutic molecules. In 1999, Vertex established a UK research and development site to utilize European sources of expertise in the field of structural biology. Vertex currently has a number of compounds in clinical development, including drug candidates for cystic fibrosis and rheumatoid arthritis, plus their lead compound, telaprevir – an oral protease inhibitor for the treatment of hepatitis V viral infection.
Vertex’s current research programme at Diamond Light Source will use X-ray crystallographic techniques to focus on the interaction of small molecule inhibitors with proteins implicated in a variety of human cancers, bacterial infection and the development of immune diseases. The exquisitely fine detail revealed by Diamond’s X-rays will allow Vertex scientists to understand how the inhibitor compounds may be improved to increase their potency and selectivity for the desired protein target. Ultimately, this will lead to the discovery of more efficacious therapeutic drugs.. The exceptional quality and intensity of light produced by the Diamond synchrotron will enable Vertex scientists to generate data and resolve new structures from ever smaller crystals and within shorter timeframes than ever before, effectively speeding up the drug discovery process and allowing even the most complex drug targets to be tackled.
Dr Graham Cheetham, a Research Fellow at Vertex, carried out preliminary trials at Diamond in December 2007 and was impressed with the facility’s resources. He says: “Vertex continuously seeks new technologies and new methods that will improve our drug discovery and development efforts, and Diamond’s synchrotron brings to Vertex a novel tool for advancing our capabilities. To conduct cutting-edge science you need cutting-edge tools, and Diamond is a centre of excellence when it comes to its equipment and scientists.”
The benefits of using Diamond are recognised companywide. Dr Julian Golec, Senior Vice President, Vertex UK, says: “We believe synchrotron research will continue to play a major role in our drug discovery and development efforts, and we look forward to our continued work with Diamond in the UK. Vertex is committed to developing drugs for serious diseases. As our targets for medical intervention become more complex, state of the art facilities and technologies like those at Diamond are central to our continued progress in the understanding of biological processes that enable innovative drug design.”
Gerd Materlik, Chief Executive at Diamond, welcomes other industrial scientists who would like to come and visit Diamond to discover how it can aid their research. He says: “Synchrotrons are well established as valuable aids to industrial research in many areas, from structural biology through to engineering. Diamond has a wide range of applications and is, therefore, an essential tool to numerous fields of scientific research. There are many companies that may be able to benefit from using the outstanding tools and expertise that we have at this cutting-edge facility. Beamtime varies in cost depending on a number of factors, such as: length of time required for experiments; complexity; and level of support required.”
Sarah Bucknall | alfa
Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs
16.01.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Cholera bacteria infect more effectively with a simple twist of shape
13.01.2017 | Princeton University
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.
The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...
UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration
"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...
Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.
Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
16.01.2017 | Power and Electrical Engineering
16.01.2017 | Information Technology
16.01.2017 | Power and Electrical Engineering